共 49 条
- [43] Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA)/cisplatin (DDP) ± Paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV(M0): An extended phase II study of the AIO/ARO/ACO ANNALS OF ONCOLOGY, 2004, 15 : 231 - 231
- [44] Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
- [46] Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S27 - S27
- [47] Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) plus abiraterone acetate plus prednisone (AA plus P) plus leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa). JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
- [48] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) plus androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)